MD Anderson and BridgeBio Pharma Launch Navire Pharma to Develop Targeted Therapy for Patients with Difficult-to-Treat Cancer

HOUSTON and PALO ALTO, Calif., Oct. 4, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically-driven and treatment-resistant cancer. BridgeBio has committed $30 million and a team of senior business managers to the company, while MD Anderson, through its Institute […]